Can a low-dose blood thinner protect people with advanced kidney disease from heart attacks and strokes?

If you have advanced kidney disease, your risk of a heart attack or stroke is frighteningly high. Yet, you're often left out of the very trials that test the medications designed to prevent these events. Why? Because doctors worry that blood thinners might cause dangerous bleeding in people with kidney problems. This leaves a huge gap in care for a vulnerable population. The TRACK trial aimed to fill that gap. It was a major global study that enrolled over 1,700 people with advanced kidney disease or those on dialysis, all of whom were also at high risk for heart disease. The question was simple but critical: could a very low dose of a common blood thinner called rivaroxaban safely reduce their risk of major heart events? The trial was designed to be extremely careful—it was quadruple-blind, meaning no one involved knew who was getting the real medication or a placebo. The goal was to see if this low-dose strategy could finally provide a protective shield against heart attacks and strokes for people who have been waiting for answers. The results will tell us if this approach works and is safe enough for this specific group of patients.